Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed amning

Janusmed amning – Zeffix

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Lamivudin Testmiljö

Lamivudin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720-7.

  2. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19:587-95.

  3. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr. 2007;44:286-91.

  4. Pirillo MF, Scarcella P, Andreotti M, Jere H, Buonomo E, Sagno JB et al. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat. 2015;22:289-96.

  5. Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53:1170-6.

  6. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18:585-90.

  7. Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther. 2012;17:1511-9.

  8. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327-33.

  1. Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720-7.
  2. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19:587-95.
  3. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr. 2007;44:286-91.
  4. Pirillo MF, Scarcella P, Andreotti M, Jere H, Buonomo E, Sagno JB et al. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat. 2015;22:289-96.
  5. Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53:1170-6.
  6. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18:585-90.
  7. Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther. 2012;17:1511-9.
  8. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327-33.

Innehållet senast uppdaterat 11/7/2024